MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$19,638K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of available-for-sale...
Accrued expenses and other curre...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
Purchases of available-for-sale ...
Operating lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-27,482
42,281
-20,393
-44,947
Stock-based compensation expense
2,268
-6,607
3,010
6,149
Depreciation
1,265
-2,742
1,324
2,693
Loss on fixed assets write-off
-181
-
0
181
Non-cash lease expense
1,355
-2,601
1,272
2,664
Accretion of discounts on available-for-sale marketable securities
195
-2,170
705
1,825
Deferred revenue and collaboration advance
-
-
-7,574
-10,417
Amortization of non-cash collaboration revenue
0
-212
125
87
Change in fair value of long-term investments
-1,292
-
0
1,292
Income tax payable
-
-
-
0
Impairment of right of use assets
634
-
-
-
Accounts receivable
0
-8
87
-384
Prepaid expenses and other assets
-553
3,597
-1,140
-2,687
Accounts payable
319
87
-1,576
2,284
Deferred revenue
257
-748
-
-
Accrued expenses and other current liabilities
2,915
-3,576
4,023
-2,476
Operating lease liabilities
-1,466
2,675
-1,328
-2,818
Other non-current liabilities
64
91
-234
143
Net cash used in operating activities
-19,513
44,171
-21,253
-44,093
Purchases of property and equipment
125
-464
74
415
Proceeds from sale of property and equipment
-37
-
0
37
Purchases of available-for-sale marketable securities
3,907
-10,111
6,063
40,796
Maturities of available-for-sale marketable securities
37,200
-77,715
33,500
84,974
Net cash provided by investing activities
33,168
-67,177
27,363
43,800
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs
-
-
-
0
Proceeds from issuance of common stock under the equity incentive plan and espp
-
-
109
-
Proceeds from issuance of common stock under the espp
74
-
-
-
Payment of deferred financing costs
7
-512
187
352
Proceeds from issuance of common stock under espp
-
-
-
109
Net cash provided by (used in) financing activities
67
403
-187
-243
Net decrease in cash, cash equivalents and restricted cash
13,722
-22,603
5,923
-536
Cash, cash equivalents and restricted cash at beginning of period
38,021
38,021
32,634
-
Cash, cash equivalents and restricted cash at end of period
43,421
-
-
-
Deferred finance issuance costs included in accounts payable, accrued expenses and other current liabilities
2
-
-
-
Cash and cash equivalents
39,028
-
-
-
Restricted cash
4,393
-
-
-
Cash, cash equivalents and restricted cash at end of period
43,421
29,699
38,021
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of
available-for-sale marketable...
$37,200K
(-56.22%↓ Y/Y)
Proceeds from issuance of
common stock under the...
$74K
Net cash provided by
investing activities
$33,168K
(-24.27%↓ Y/Y)
Net cash provided by
(used in) financing...
$67K
(127.57%↑ Y/Y)
Canceled cashflow
$4,069K
Canceled cashflow
$7K
Net decrease in
cash, cash...
$13,722K
(2660.07%↑ Y/Y)
Canceled cashflow
$19,513K
Purchases of
available-for-sale marketable...
$3,907K
(-90.42%↓ Y/Y)
Purchases of property and
equipment
$125K
(-69.88%↓ Y/Y)
Proceeds from sale of
property and equipment
-$37K
(-200.00%↓ Y/Y)
Accrued expenses and
other current...
$2,915K
(217.73%↑ Y/Y)
Stock-based compensation
expense
$2,268K
(-63.12%↓ Y/Y)
Non-cash lease expense
$1,355K
(-49.14%↓ Y/Y)
Depreciation
$1,265K
(-53.03%↓ Y/Y)
something is missing
$1,111K
Impairment of right of use
assets
$634K
Prepaid expenses and
other assets
-$553K
(79.42%↑ Y/Y)
Accounts payable
$319K
(-86.03%↓ Y/Y)
Deferred revenue
$257K
Loss on fixed assets
write-off
-$181K
(-200.00%↓ Y/Y)
Other non-current
liabilities
$64K
(-55.24%↓ Y/Y)
Payment of deferred
financing costs
$7K
(-98.01%↓ Y/Y)
Net cash used in
operating activities
-$19,513K
(55.75%↑ Y/Y)
Canceled cashflow
$10,922K
Net loss
-$27,482K
(38.86%↑ Y/Y)
Operating lease
liabilities
-$1,466K
(47.98%↑ Y/Y)
Change in fair value of
long-term investments
-$1,292K
(-200.00%↓ Y/Y)
Accretion of discounts on
available-for-sale marketable...
$195K
(-89.32%↓ Y/Y)
Buy us a coffee
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)